|
Feb 18, 21:11
|
Merck (MRK) Valuation Check As Keytruda SC Approval And Mayo Clinic AI Deal Shape Growth Story
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 16:20
|
Moderna stock surges as FDA reverses course, agrees to review new flu shot
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 16:03
|
Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 15:17
|
Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 11:45
|
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 10:16
|
$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 08:06
|
The Patent Cliff Is a Hill: Why Merck's Diversification Engine Makes MRK a Buy
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 07:46
|
Merck And Mayo Clinic Announce R&D Agreement To Apply AI, Advanced Analytics And Multimodal Clinical Data To Support Drug Discovery And Development
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 21:01
|
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 19:14
|
Did New KEYTRUDA Approvals Just Shift Merck’s (MRK) Post-Patent Oncology Investment Narrative?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 16:00
|
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 15:00
|
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 14:48
|
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 12:03
|
Merck's KEYTRUDA SC Receives Health Canada Approval
|
N/A |
—
|
—
|
No analysis
|
|
Feb 16, 16:45
|
Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period
|
N/A |
—
|
—
|
No analysis
|
|
Feb 14, 04:26
|
Merck’s KEYTRUDA Wins New Ovarian Cancer Use As Valuation Gap Persists
|
N/A |
—
|
✓
|
# MRK News Report — 2026-02-14
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | MRK |
| **Date** | 2026-02-14 |
| **Total Articles**...
|
|
Feb 13, 16:38
|
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 15:49
|
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:57
|
Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:36
|
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:30
|
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:00
|
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 09:32
|
Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 04:33
|
3 Mega-Cap Stocks for Long-Term Investors
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 20:30
|
Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 11:45
|
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
|
N/A |
—
|
✓
|
# MRK News Report — 2026-02-12
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | MRK |
| **Date** | 2026-02-12 |
| **Total Articles**...
|
|
Feb 12, 11:27
|
Sanofi replaces chief Paul Hudson with Merck executive after R&D woes
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 11:10
|
Merck’s Ovarian Cancer Wins Tested Against Valuation Gap And Momentum
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 09:00
|
Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 07:49
|
Merck To Present Data Across Multiple Genitourinary Cancers From Several Approved And Investigational Medicines At 2026 ASCO GU Cancers Symposium
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 20:44
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 16:33
|
Merck & Co. Inc. stock outperforms competitors on strong trading day
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 14:56
|
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 13:55
|
Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 11:45
|
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 11:45
|
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 11:26
|
Merck's Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 07:51
|
The FDA Approves Merck's Keytruda And Keytruda Qlex Plus Paclitaxel, With Or Without Bevacizumab, For PD-L1+ Platinum-resistant Ovarian Carcinoma
|
N/A |
—
|
—
|
No analysis
|